Participants
obesity, illness, allergic reaction, advanced-stage cancer, end-stage renal disease, chronic liver disease
OBESITY, ALLERGIC REACTION, END-STAGE RENAL DISEASE, TRANSFUSION REACTION, CHRONIC LIVER DISEASE
A total of 136 eligible participants were included in the study. To be eligible, participants had to be Thai individuals over 20 years old and have a mild-to-moderate COVID-19 diagnosis confirmed by PCR testing and a body weight of 40 kg or more. Participants were required to have at least one risk factor associated with the potential deterioration to severe illness, including age over 60 years, obesity or body mass index (BMI) of 30 kg/mPregnant or breastfeeding individuals, those with severe COVID-19 requiring oxygen therapy or hospitalization, individuals on anti-SARS-CoV-2 therapy for more than 24 hours, those with chronic liver disease Child–Pugh score C or end-stage renal disease or advanced-stage cancer, those who had received neutralizing monoclonal antibody or plasma within the past 60 days, or those who had a history of severe allergic reaction to FPV or sotrovimab or severe transfusion reaction were excluded from the study (Flow of enrollment and allocation.